

A Mystery of the Inhibitors of Human Neutrophil Elastase. Why they are mostly not active in clinical trials and could the system of autoimmune response to human elastin be responsible for that?

Jozef Oleksyszyn*

Professor Emeritus, Division of Organic and Medical Chemistry, Faculty of Chemistry, Wrocław University Sciences and Technology, Wybrzeże Wyspińskiego 27, 50-370 Wrocław, Poland

***Corresponding Author:** Jozef Oleksyszyn, Professor Emeritus, Division of Organic and Medical Chemistry, Faculty of Chemistry, Wrocław University Sciences and Technology, Wybrzeże Wyspińskiego 27, 50-370 Wrocław, Poland.

Received: January 08, 2025; **Published:** January 13, 2025

Abstract

Degradation of the extracellular matrix (ECM) is part of the pathology process of many diseases. Human neutrophil elastase (HNE) is responsible for degradation of the elastin and formation of the elastin fragments, well known mediators of inflammation and inducer of anti-elastin antibodies synthesis. Therefore, HNE is a subject of intense investigation in drug design and clinical studies to prevent elastase-mediated pathology. More than 15 clinical studies were reported in literature without success and only ONO-5046, HNE inhibitor has been approved for clinical use in Japan and Korea Republic, but not in USA. Any type of inhibitor, always bears structural similarity to the natural substrate of the enzyme. They occupied this same region of the enzyme. For HNE natural substrate is the elastin, therefore antibodies to elastin, have to bind inhibitors of HNE also. This resulted in „neutralisation” of inhibitors by removing them from place of their action and lack of activity of HNE inhibitors in the clinical trials. It could be a general rule concerning all the enzymes degrading ECM (extracellular matrix) as before was noticed in case of collagens. However, no attempts to the explanation were presented.

In 1968 Janoff and Scherer, first reported that human neutrophil elastase (at this time called polymorphonuclear leukocyte elastase) is a main mediator of inflammation, induced by the human neutrophils [1]. Today it is clear that uncontrolled activity of human neutrophil elastase is one of the main factors driving pathological processes during a large number of diseases. Therefore, the design and synthesis of inhibitors of human neutrophil elastase are active projects at many academic and industrial institutions [2]. Recently, use of the inhibitors of HNE become an interesting approach to anticancer treatment also [3]. Inhibitors of HNE are intensively investigated in clinical trials and at least 15 of them are reported in literature.

Only two of such substances are approved for the use in human patients. A first one is a Prolactin (human, natural alpha-1-proteinase inhibitor alpha-1-PI, isolated from human blood plasma) for augmentation and maintenance therapy in individuals with alpha-1-proteinase inhibitor genetic deficiency and clinical evidence of emphysema. It is not a typical, small molecular weight drug and its use is just to correct the level of alpha-1-PI. The second one is sivelestat (ONO-5046 from ONO Pharmaceutical) nonpeptidic inhibitor, approved for clinical use in Japan and Korea Republic but not in USA [4].

Citation: Jozef Oleksyszyn. (2025). A Mystery of the Inhibitors of Human Neutrophil Elastase. Why they are mostly not active in clinical trials and could the system of autoimmune response to human elastin be responsible for that? *Journal of Pharmacy and Drug Development* 7(1).

Ono-5046, N-{2-[4-(2,3-Dimethylpropionyloxy) phenylsulfonyl amino]} benzoyl} aminoacetic acid, is a competitive inhibitor of the HNE with $K_i = 200$ nM. It has unique structure, not similar to the natural substrate of the enzyme where elastin possess several times repeated fragments of Val-Gly-Val-Ala-Pro-Gly [5]. Fragments of extracellular matrix are known to be an inflammatory mediator and frequently induce an antibody synthesis also [6]. Clearly, the HNE recognised such fragments of elastin and proteolytically hydrolysed peptide bound at Valine-carboxylamide residue. The methoxy-succinyl- Ala-Ala-Pro-Val-(p-nitroanilide) is an excellent chronogeny substrate of HNE, frequently used in the kinetic investigation of enzyme inhibition [7]. Process of design the structure of inhibitors for serine protease (and in fact for any enzymes) start with the analysis of the structure of best substrate for the enzyme. Sometimes, a small change in the structure of best substrate molecules could provide us a quite good inhibitor for given enzyme. In another words, for the inhibitor of HNE, its structure has to contain structural fragment similar as much as possible, to the structure of Val-Pro-Val in the region responsible for its binding. The HNE possess a pocket, perfectly profiled to bind this unit which we well know from the investigation the structure of best substrate. These elements of the substrate structure, decide about the specificity of the enzyme also.

All inhibitors of the HNE unsuccessfully investigated in clinical studies contain such fragment. Sometimes is not easy to see that at flat 2D drawing, but 3D picture clearly could these visualized. Very instructive here, is the example of the beta-lactam antibiotics, which are mimetics of acyl-D-alanyl-D-alanine, as first reported by Tipper and Strominger [8]. Anti-elastin antibodies, polyclonal in nature, bind a variety of fragments of elastin and just by an accident could bind that one, which is recognised by the substrate binding pocket of HNE also. Because of this structural similarity, the elastin antibodies should bind also the inhibitors of HNE and removed them from the side of pathological process and decrease their effective concentration. As results, we will see that clinical trials at Phase III will not show the Pharmacology efficacy. Recently a new generation of non-peptidyl inhibitors of HNE, on the base of dihydropyridine scaffold were reported [12,13]. They are very potent inhibitors of HNE with K_i in picomolar range and designed to inhibit Proteinase 3 simultaneously [13]. Such dihydropyridine scaffold are used to build up the mimetic of bioactive conformation of substrate for HNE and introduce this fragment to the structure of designed inhibitor. We can only hope that such bioactive conformation is not similar (or identical) to conformation of elastin in the region of

binding of HNE. In such case inhibitors will be bind effectively by the elastin antibodies before they have a chance to inhibit HNE in vivo (and proteinase 3). In fact, it could be a general phenomenon concerning all enzymes degrading extracellular matrix, where its fragments induce the synthesis of antibodies [6]. Over twenty years ago, Greenwald pointed out similar problem with the matrix metalloproteinases (MMP's) inhibitors which, even today, after more than forty years of investigation in clinic, did not result in a new drug [14]. MMP's are responsible for the collagen's degradation. Collagen fragments, are immunogenic [6], and probably in vivo the collagen antibodies, are able to bind the inhibitors of MMP's also.

In 1996 Paul suggest that catalytic antibodies may be a fairly routine component of natural immune response [15]. They are frequently discovered in normal and pathological conditions [16]. The crystal structure of active hydrolytic antibodies with a phosphate-type transition state analog (hapten) bound to the active site has been resolved [17]. This antibody active site contain a Ser-His dyad structure instead of the Ser-His-Asp catalytic triad of serine protease. We do not know if synthesis of such type of anti-elastin antibodies take place in vivo and no one reported that yet. If this really occur, it will complicate picture even more, mainly because the possibility of neutralisation of natural inhibitors of proteases as alpha-1-proteinase and alpha-2-macroglobulin and others, small molecular weight proteins that are inhibitory for serine proteases [18]. If these take place in vivo, need to be investigated.

It seems, we have a kinetic trap, leading to the neutralisation of HNE inhibitors, set up by the structural chemistry (which in fact is an autoimmune response). There is not an obvious solution. However, we could try to establish a new assay to measure binding of the inhibitors HNE to the human anti-elastin antibodies and tested in such system all inhibitors of HNE which we have in our libraries of compounds. As a standard we should use a Sivelestat (ONO-5046), the only HNE inhibitor, which reach the market. ONO-5046 probably does not bind (or very weakly bind) to the human elastin antibodies. (a problem here, could be an evolution of antibodies undergoing during immune response?). A new, effective in vivo inhibitor of HNE need to have an identical profile – does not bind to elastin antibodies and being a good inhibitor of HNE. These searches could bring us a new lead structure to a new type, of an effective in vivo inhibitor of HNE. Alternatively, we need to establish a new way to design inhibitors, which could omitted the limitation formed by structural chemistry/ autoimmune response to the human elastin. (If it is possible?).

Citation: Jozef Oleksyszyn. (2025). A Mystery of the Inhibitors of Human Neutrophil Elastase. Why they are mostly not active in clinical trials and could the system of autoimmune response to human elastin be responsible for that? *Journal of Pharmacy and Drug Development* 7(1).

References

1. A. Janoff, J. Scheres, (1968). Mediators of inflammation In leukocyte lysosome. Elastolytic activity in granules of human polymorphonuclear leukocytes. *Journal of Experimental Medicine*. 128 1137-1155.
2. On the PUB MED (PUBLIC MEDLINE) the key word „neutrophil elastase inhibitors” gives 25 047 results, when neutrophil elastase inhibitors review 3093 results, December 2024.
3. W. Jia, W. Mao, Q., et al., (2024). Targeting neutrophil elastase is a promising direction for future cancer treatment. *Discover Oncology* 15 167-182.
4. N. Aikawa, Y. Kawasaki, (2014). Clinical utility of the neutrophil elastase inhibitor silvestat for the treatment of acute respiratory distress syndrome. *Therapy Clinical Risk Management* 10621-629.
5. N. Floquet, et al. (2004). Structural characterization of VGAPG an elastin-driven peptide Peptide. *Science* 75 266-280.
6. T.L. Adar-Kirk, R.M. Senior, (2008). Fragments of extracellular Matrix as Mediators of Inflammation. *International Biochemistry Cell Biology*. 40 1101-1110.
7. J. Oleksyszyn, J.C. Powers, (1994). Amino Acid and peptide phosphonate derivatives as specific inhibitor of serine protease. *Methods In Enzymology*, 244 423-461.
8. D.J. Tipper, J.L. Strominger, (1965). Mechanism of action of penicillin a proposal based on their structural similarity to acyl-D-alanyl-D-alanine. *Proceeding National Academy of Sciences*, 54 1133-1141.
9. L. Crocetti et al., (2019). A patent perspective on human neutrophil elastase (HNE) inhibitors (2014-2018) and their therapeutic applications. *Expert Opinion Therapeutic Patent*. 29 555-578.
10. J.S. Ocampo-Gallego et al., (2024). HNE inhibitor classification, biological-synthetic sources. *Fundamental and Clinical Pharmacology*, 38 13-32.
11. W.C. Groutas, D. Dengfang K.R. Alliston, (2011). Neutrophil Elastase Inhibitors. *Expert Opinion Therapeutic Patents*. 21 339-354.
12. F. Nussbaum et al., (2015). Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY-85-6501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases. *ChemMedChem*. 10 1163-1173.
13. P. Gartan et al., (2024). Investigating Polypharmacology Through Targeting Known Human Neutrophil Inhibitors to Proteinase 3. *Journal of Chemical Information and Modeling* 64 621-626.
14. R.A. Greenwald, (1999). Thirty-six Years in the clinic without an MMP Inhibitors: What Hath Collagenase Wrought? *Annals of The New York Academy of Sciences* Jan 30: 878: 413-9.
15. S. Paul, (1996). Natural Catalytic Antibodies. *Molecular Biotechnology*, 5 197-202.
16. G.A. Nevinski, V.N. Buneva, (2010). Natural Catalytic Antibodies in Norm, Autoimmune, Viral and Bacterial Diseases. *The Scientific World Journal*, 10 1203-1233.
17. G.W. Zhou, J. Guo, W. Huang, R.J. Fletterick, T.S. Scanlon. (1994). Crystal Structure of Catalytic Antibodies with a Serine Protease Active Site. *Science* 2651059-1064.
18. Proteinase Inhibitors. Editors A.J. Barrett, G. Salvesen. (1986). Amsterdam: New York: Elsevier.

Benefits of Publishing with EScientific Publishers:

- ❖ Swift Peer Review
- ❖ Freely accessible online immediately upon publication
- ❖ Global archiving of articles
- ❖ Authors Retain Copyrights
- ❖ Visibility through different online platforms

Submit your Paper at:

<https://escientificpublishers.com/submission>